Discovery of a subtype-selective, covalent inhibitor against palmitoylation pocket of TEAD3
2021
发表期刊ACTA PHARMACEUTICA SINICA B (IF:14.7[JCR-2023],14.1[5-Year])
ISSN2211-3835
EISSN2211-3843
卷号11期号:10页码:3206-3219
发表状态已发表
DOI10.1016/j.apsb.2021.04.015
摘要

The TEA domain (TEAD) family proteins (TEAD-4) are essential transcription factors that control cell differentiation and organ size in the Hippo pathway. Although the sequences and structures of TEAD family proteins are highly conserved, each TEAD isoform has unique physiological and pathological functions. Therefore, the development and discovery of subtype selective inhibitors for TEAD protein will provide important chemical probes for the TEAD-related function studies in development and diseases. Here, we identified a novel TEAD1/3 covalent inhibitor (DC-TEAD in 1072) with biochemical IC50 values of 0.61 +/- 0.02 and 0.58 +/- 0.12 mu mol/L against TEAD1 and TEAD3, respectively. Further chemical optimization based on DC-TEAD in 1072 yielded a selective TEAD3 inhibitor DC-TEAD3 in 03 with the IC50 value of 0.16 +/- 0.03 mmol/L, which shows 100-fold selectivity over other TEAD isoforms in activity-based protein profiling (ABPP) assays. In cells, DC-TEAD3 in 03 showed selective inhibitory effect on TEAD3 in GAL4-TEAD (1-4) reporter assays with the IC50 value of 1.15 mmol/L. When administered to zebrafish juveniles, experiments showed that DC-TEAD3in03 reduced the growth rate of zebrafish caudal fins, indicating the importance of TEAD3 activity in controlling proportional growth of vertebrate appendages. (C) 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.

关键词Hippo pathway TEAD3 Covalent inhibitor Palmitoylation inhibitor
收录类别SCIE
语种英语
WOS研究方向Pharmacology & Pharmacy
WOS类目Pharmacology & Pharmacy
WOS记录号WOS:000710908100004
出版者INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
原始文献类型Article
引用统计
正在获取...
文献类型期刊论文
条目标识符https://kms.shanghaitech.edu.cn/handle/2MSLDSTB/128522
专题生命科学与技术学院_硕士生
生命科学与技术学院_PI研究组_Christopher Lee Antos组
生命科学与技术学院_特聘教授组_陈凯先组
生命科学与技术学院_本科生
通讯作者Zhou, Bing; Antos, Christopher L.; Luo, Cheng
作者单位
1.Nanjing Univ Chinese Med, Sch Chinese Mat Med, Nanjing 210023, Peoples R China;
2.Chinese Acad Sci, Ctr Chem Biol, Drug Discovery & Design Ctr, Shanghai Inst Mat Med,State Key Lab Drug Res, Shanghai 201203, Peoples R China;
3.Chinese Acad Sci, Shanghai Inst Mat Med, Dept Med Chem, State Key Lab Drug Res, Shanghai 201203, Peoples R China;
4.Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA;
5.ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China;
6.Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, Shanghai 200240, Peoples R China;
7.Chinese Acad Sci, Shanghai Inst Mat Med, Dept Analyt Chem, Shanghai 201203, Peoples R China;
8.Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, Shanghai 201203, Peoples R China;
9.Nanchang Univ, Sch Pharm, Nanchang 330006, Jiangxi, Peoples R China;
10.Univ Paris, Pharmacol & Toxicol Chem & Biochem Lab, UMR 8601 CNRS, F-75270 Paris 06, France;
11.Univ Chinese Acad Sci, Sch Pharmaceut Sci & Technol, Hangzhou Inst Adv Study, Hangzhou 310024, Peoples R China
通讯作者单位生命科学与技术学院
推荐引用方式
GB/T 7714
Lu, Tian,Li, Yong,Lu, Wenchao,et al. Discovery of a subtype-selective, covalent inhibitor against palmitoylation pocket of TEAD3[J]. ACTA PHARMACEUTICA SINICA B,2021,11(10):3206-3219.
APA Lu, Tian.,Li, Yong.,Lu, Wenchao.,Spitters, Twgm.,Fang, Xueyu.,...&Luo, Cheng.(2021).Discovery of a subtype-selective, covalent inhibitor against palmitoylation pocket of TEAD3.ACTA PHARMACEUTICA SINICA B,11(10),3206-3219.
MLA Lu, Tian,et al."Discovery of a subtype-selective, covalent inhibitor against palmitoylation pocket of TEAD3".ACTA PHARMACEUTICA SINICA B 11.10(2021):3206-3219.
条目包含的文件
文件名称/大小 文献类型 版本类型 开放类型 使用许可
个性服务
查看访问统计
谷歌学术
谷歌学术中相似的文章
[Lu, Tian]的文章
[Li, Yong]的文章
[Lu, Wenchao]的文章
百度学术
百度学术中相似的文章
[Lu, Tian]的文章
[Li, Yong]的文章
[Lu, Wenchao]的文章
必应学术
必应学术中相似的文章
[Lu, Tian]的文章
[Li, Yong]的文章
[Lu, Wenchao]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。